Method for predicting responsiveness to cancer treatment using p300-inhibiting compound
AssigneesNational Cancer Center, Daiichi Sankyo Company, Limited
InventorsTakashi Kohno, Hideaki Ogiwara, Yuichi Tominaga, Saito Higuchi
Life of this patent
Estimating the term…
Abstract
It has been found that CBP and p300 are in the relationship of synthetic lethality, and treatment inhibiting p300 is a promising approach for the treatment of CBP-mutated cancer. It has also been revealed that this therapeutic strategy achieves efficient treatment based on companion diagnostics because a p300 inhibitor can be administered to a cancer patient selected with functional suppression of CBP as an index.
Claims12
A method for improving the response rate of the treatment of cancer, comprising using a biological sample derived from a cancer patient, detecting the presence of a CBP mutation contained in the biological sample, determining the patient is responsive to the treatment of cancer with a compound inhibiting p300, and treating the patient by a method consisting of administrating to the patient an amount of a compound inhibiting p300 and a pharmaceutically acceptable carrier effective to suppress the growth of cancer cells, wherein the mutation is a homozygous CBP deletion, a nonsense mutation, or one of the mutations Asn83Thr, Ser893Leu, Arg1446Cys, Trp1472Cys, Asn2175Ser, Glu1835Stop, Asn2111Ser, Leu551Ile, Gly1411Glu, or Ala2044Gly.
A method for improving the response rate of the treatment of cancer, comprising using a biological sample derived from a cancer patient, detecting the presence of a CBP mutation in the biological sample, selecting the patient as the candidate for the treatment of cancer with a compound inhibiting p300, and treating the patient by a method consisting of administrating to the patient an amount of a compound inhibiting p300 and a pharmaceutically acceptable carrier effective to suppress the growth of cancer cells, wherein the mutation is a homozygous CBP deletion, a nonsense mutation, or one of the mutations Asn83Thr, Ser893Leu, Arg1446Cys, Trp1472Cys, Asn2175Ser, Glu1835Stop, Asn2111Ser, Leu551Ile, Gly1411Glu, or Ala2044Gly.
A method for treating cancer having functional suppression of CBP, comprising using a biological sample derived from a cancer patient, detecting the presence of functional suppression of CBP contained in the biological sample, and treating the patient by a method consisting of administering to the patient an amount of a compound inhibiting p300 and a pharmaceutically acceptable carrier effective to suppress the growth of cancer cells, and suppressing the growth of the cancer cells to the patient.
A method for treating a cancer patient, wherein the patient has been determined to have functional suppression of CBP, comprising treating the patient by a method consisting of administering to the patient an amount of a compound inhibiting p300 and a pharmaceutically acceptable carrier effective to suppress the growth of cancer cells, and suppressing the growth of the cancer cells.
Dependencies are inferred from the claim text.